Brief: JW Therapeutics Announces IND Approval For The Clinical Trial Of Carteyva
20/04/2022 11:31
April 20 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* JW THERAPEUTICS ANNOUNCES IND APPROVAL FOR THE CLINICAL
TRIAL OF
CARTEYVA® IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR
REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Source text for Eikon: ID:nPn7tqRk9a
Further company coverage: 2126.HK
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License